Ad5‐nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants
Abstract Little information is available for antibody levels against SARS‐CoV‐2 variants of concern induced by Omicron breakthrough infection and a third booster with an inactivated vaccine (InV) or Ad5‐nCoV in people with completion of two InV doses. Plasma was collected from InV pre‐vaccinated Omicron‐infected patients (OIPs), unvaccinated OIPs between 0 and 22 days, and healthy donors (HDs) 14 days or 6 months after the second doses of an InV and 14 days after a homogenous booster or heterologous booster of Ad5‐nCoV. Anti‐Wuhan‐, Anti‐Delta‐, and Anti‐Omicron‐receptor binding domain (RBD)‐IgG titers were detected using enzyme‐linked immunosorbent assay. InV pre‐vaccinated OIPs had higher anti‐Wuhan‐, anti‐Delta‐, and anti‐Omicron‐RBD‐IgG titers compared to unvaccinated OIPs. Anti‐Wuhan‐RBD‐IgG titers sharply increased in InV pre‐vaccinated OIPs 0–5 days postinfection (DPI), while the geometric mean titers (GMTs) of anti‐Delta‐ and anti‐Omicron‐RBD‐IgG were 3.3‐fold and 12.0‐fold lower. Then, the GMT of anti‐Delta‐ and anti‐Omicron‐RBD‐IgG increased to 35 112 and 28 186 during 11–22 DPI, about 2.6‐fold and 3.2‐fold lower, respectively, than the anti‐Wuhan‐RBD‐IgG titer. The anti‐Wuhan‐, anti‐Delta‐, and anti‐Omicron‐RBD‐IgG titers declined over time in HDs after two doses of an InV, with 25.2‐fold, 5.6‐fold, and 4.5‐fold declination, respectively, at 6 months relative to the titers at 14 days after the second vaccination. Anti‐Wuhan‐, anti‐Delta‐, and anti‐Omicron‐RBD‐IgG titers elicited by a heterologous Ad5‐nCoV booster were significantly higher than those elicited by an InV booster, comparable to those in InV pre‐vaccinated OIPs. InV and Ad5‐nCoV boosters could improve humoral immunity against Omicron variants. Of these, the Ad5‐nCoV booster is a better alternative..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Journal of Medical Virology - 95(2023), 1 |
| Beteiligte Personen: |
Kong, Weiya [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 Wiley Periodicals LLC. |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1002/jmv.28163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY009007717 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY009007717 | ||
| 003 | DE-627 | ||
| 005 | 20231111175707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230217s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/jmv.28163 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_JMV_2023_95_1.zip.xml |
| 035 | |a (DE-627)WLY009007717 | ||
| 035 | |a (WILEY)JMV28163 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Kong, Weiya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ad5‐nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants |
| 264 | 1 | |c 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Abstract Little information is available for antibody levels against SARS‐CoV‐2 variants of concern induced by Omicron breakthrough infection and a third booster with an inactivated vaccine (InV) or Ad5‐nCoV in people with completion of two InV doses. Plasma was collected from InV pre‐vaccinated Omicron‐infected patients (OIPs), unvaccinated OIPs between 0 and 22 days, and healthy donors (HDs) 14 days or 6 months after the second doses of an InV and 14 days after a homogenous booster or heterologous booster of Ad5‐nCoV. Anti‐Wuhan‐, Anti‐Delta‐, and Anti‐Omicron‐receptor binding domain (RBD)‐IgG titers were detected using enzyme‐linked immunosorbent assay. InV pre‐vaccinated OIPs had higher anti‐Wuhan‐, anti‐Delta‐, and anti‐Omicron‐RBD‐IgG titers compared to unvaccinated OIPs. Anti‐Wuhan‐RBD‐IgG titers sharply increased in InV pre‐vaccinated OIPs 0–5 days postinfection (DPI), while the geometric mean titers (GMTs) of anti‐Delta‐ and anti‐Omicron‐RBD‐IgG were 3.3‐fold and 12.0‐fold lower. Then, the GMT of anti‐Delta‐ and anti‐Omicron‐RBD‐IgG increased to 35 112 and 28 186 during 11–22 DPI, about 2.6‐fold and 3.2‐fold lower, respectively, than the anti‐Wuhan‐RBD‐IgG titer. The anti‐Wuhan‐, anti‐Delta‐, and anti‐Omicron‐RBD‐IgG titers declined over time in HDs after two doses of an InV, with 25.2‐fold, 5.6‐fold, and 4.5‐fold declination, respectively, at 6 months relative to the titers at 14 days after the second vaccination. Anti‐Wuhan‐, anti‐Delta‐, and anti‐Omicron‐RBD‐IgG titers elicited by a heterologous Ad5‐nCoV booster were significantly higher than those elicited by an InV booster, comparable to those in InV pre‐vaccinated OIPs. InV and Ad5‐nCoV boosters could improve humoral immunity against Omicron variants. Of these, the Ad5‐nCoV booster is a better alternative. | ||
| 700 | 1 | |a Zhong, Qingyang |4 aut | |
| 700 | 1 | |a Chen, Mingxiao |4 aut | |
| 700 | 1 | |a Yu, Pei |4 aut | |
| 700 | 1 | |a Xu, Ruhong |4 aut | |
| 700 | 1 | |a Zhang, Lei |4 aut | |
| 700 | 1 | |a Lai, Changchun |4 aut | |
| 700 | 1 | |a Deng, Min |4 aut | |
| 700 | 1 | |a Zhou, Qiang |4 aut | |
| 700 | 1 | |a Xiong, Shilong |4 aut | |
| 700 | 1 | |a Liang, Yuemei |4 aut | |
| 700 | 1 | |a Wan, Li |4 aut | |
| 700 | 1 | |a Lin, Meifang |4 aut | |
| 700 | 1 | |a Wang, Minhong |4 aut | |
| 700 | 1 | |a Mai, Weikang |4 aut | |
| 700 | 1 | |a Chen, Lu |4 aut | |
| 700 | 1 | |a Lei, Yu |4 aut | |
| 700 | 1 | |a Qin, Nan |4 aut | |
| 700 | 1 | |a Zhu, Jianqiang |4 aut | |
| 700 | 1 | |a Ruan, Jianfeng |4 aut | |
| 700 | 1 | |a Huang, Qiulan |4 aut | |
| 700 | 1 | |a Kang, An |4 aut | |
| 700 | 1 | |a Wang, Jun |4 aut | |
| 700 | 1 | |a Li, Wenrui |4 aut | |
| 700 | 1 | |a Ji, Tianxing |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Medical Virology |g 95(2023), 1 |w (DE-627)WLY008980918 |x 10969071 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:1 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 1 |g 9 | ||